Answers are grounded in this paper and cite their sources.
Probiotics offer a promising therapeutic avenue for inflammatory bowel disease (IBD), yet their efficacy is highly strain-specific and mechanistically complex. To address this, this study integrated complete genome sequencing, in vitro assays, and in vivo metabolomics to elucidate the anti-inflammatory mechanisms of Bifidobacterium animalis subsp. lactis BGI-N3. Genomic analysis confirmed the presence of gene clusters associated with stress tolerance and immunomodulation. Functionally, BGI-N3 suppressed LPS-induced pro-inflammatory cytokines in monocytes and significantly alleviated DSS-induced colitis in mice by restoring mucosal architecture. Crucially, untargeted metabolomics demonstrated that BGI-N3 intervention restructured the gut metabolic landscape, specifically enriching anti-inflammatory metabolites, including ergocalciferol, vanillin, and dihomo-gamma-linolenic acid (DGLA). These metabolites correlated positively with IL-10 levels and negatively with pro-inflammatory markers. Collectively, these findings provided genomic validation and insights into metabolic changes associated with the protective effects of BGI-N3, highlighting its potential as a functional probiotic for alleviating intestinal inflammation.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: